Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis

Pancreas

Volumn 36, Issue 3, 2008, Pages 255-260

  Lee, Jun Kyu ^a   Ryu, Ji Kon ^b,c   Park, Joo Kyoung ^b   Lee, Sang Hyub ^b   Yoon, Won Jae ^b   Kim, Yong Tae ^b   Jung, Hyun Chae ^b   Yoon, Yong Bum ^b  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Acute pancreatitis; Cerulein; Nafamostat; p38 MAPK; Protease inhibitor

Indexed keywords

AMYLASE; CERULETIDE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOPEROXIDASE; NAFAMSTAT MESILATE; TRIACYLGLYCEROL LIPASE;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMYLASES; ANIMALS; CAERULEIN; FEMALE; GUANIDINES; INTERLEUKIN-6; LIPASE; MICE; MICE, INBRED BALB C; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATITIS; PEROXIDASE; PROTEASE INHIBITORS;

EID: 41149162849     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815b6b10     Document Type: Article

References (50)

1. Mayerle J, Simon P, Kraft M, et al. Conservative treatment of acute pancreatitis. Med Klin (Munich). 2003;98:744-749.
2. Beger HG, Rau B, Isenmann R. Natural history of necrotizing pancreatitis. Pancreatology. 2003;3:93-101.
3. Werner J, Feuerbach S, Uhl W, et al. Management of acute pancreatitis: from surgery to interventional intensive care. Gut. 2005;54:426-436.
4. Steer ML. Frank Brooks memorial lecture: the early intraacinar cell events which occur during acute pancreatitis. Pancreas. 1998;17:31-37.
5. Hartwig W, Jimenez RE, Werner J, et al. Interstitial trypsinogen release and its relevance to the transformation of mild into necrotizing pancreatitis in rats. Gastroenterology. 1999;117:717-725.
6. Trapnell JE, Rigby CC, Talbot CH, et al. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974;61:177-182.
7. Tanaka N, Tsuchiya R, Ishii K. Comparative clinical study of FOY and Trasylol in acute pancreatitis. Adv Exp Med Biol. 1979;120:367-378.
8. Freise J, Melzer P, Schmidt FW, et al. Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. Z Gastroenterol. 1986;24:200-211.
9. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2:698-700.
10. Pederzoli P, Cavallini G, Falconi M, et al. Gabexate mesilate vs aprotinin in human acute pancreatitis. A prospective, randomized, double-blind multicenter study. Int J Pancreatol. 1993;14:117-124.
11. Chen HM, Chen JC, Hwang TL, et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47:1147-1150.
12. Ruud TE, Aasen AO, Pillgram-Larsen J, et al. Effects of protease inhibitor pretreatment on hemodynamic performances and survival rate in experimental, acute pancreatitis. Adv Exp Med Biol. 1986;198:413-421.
13. Tani S, Otsuki M, Itoh H, et al. The protective effect of the trypsin inhibitor urinastatin on cerulein-induced acute pancreatitis in rats. Pancreas. 1988;3:471-476.
14. Ono H, Hayakawa T, Kondo T, et al. Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat. Dig Dis Sci. 1990;35:787-792.
15. Hirano T, Manabe T, Tobe T. Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein. J Gastroenterol Hepatol. 1991;6:260-264.
16. Che YZ, Ikei S, Yamaguchi Y, et al. The protective effects of long-acting recombinant human pancreatic secretory trypsin inhibitor (R44S-PSTI) in a rat model of cerulein-induced pancreatitis. J Int Med Res. 1996;24:59-68.
17. Imamura M, Mikami Y, Takahashi H, et al. Effect of a specific synthetic inhibitor of neutrophil elastase (ONO-5046) on the course of acute hemorrhagic pancreatitis in dogs. J Hepatobiliary Pancreat Surg. 1998;5:422-428.
18. Keck T, Balcom JH, Antoniu BA, et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery. 2001;130:175-181.
19. Yamauchi J, Takeda K, Shibuya K, et al. Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs. Pancreatology. 2001;1:662-667.
20. Van Acker GJ, Saluja AK, Bhagat L, et al. Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol. 2002;283:G794-G800.
21. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with Trasylol: report of a controlled therapeutic trial. Br Med J. 1965;5462:627-629.
22. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978;65:337-341.
23. Valderrama R, Perez-Mateo M, Navarro S, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51:65-70.
24. Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993;104:1165-1170.
25. Messori A, Rampazzo R, Scroccaro G, et al. Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig Dis Sci. 1995;40:734-738.
26. Cortesi R, Ascenzi P, Colasanti M, et al. Cross-enzyme inhibition by gabexate mesylate: formulation and reactivity study. J Pharm Sci. 1998;87:1335-1340.
27. Pitkaranta P, Kivisaari L, Nordling S, et al. Vascular changes of pancreatic ducts and vessels in acute necrotizing, and in chronic pancreatitis in humans. Int J Pancreatol. 1991;8:13-22.
28. Nuutinen P, Kivisaari L, Schroder T. Contrast-enhanced computed tomography and microangiography of the pancreas in acute human hemorrhagic/necrotizing pancreatitis. Pancreas. 1988;3:53-60.
29. Singh VP, Chari ST. Protease inhibitors in acute pancreatitis: lessons from the bench and failed clinical trials. Gastroenterology. 2005;128:2172-2174.
30. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med. 1996;335:919-923.
31. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488-495.
32. Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs. 2003;63:1799-1812.
33. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc. 2000;51:1-7.
34. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1986;661:342-345.
35. Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155-162.
36. Mikami Y, Takeda K, Matsuda K, et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas. 2005;30:248-253.
37. Takagi K, Isaji S. Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. Pancreas. 2000;21:279-289.
38. Wagner AC, Metzler W, Hofken T, et al. p38 map kinase is expressed in the pancreas and is immediately activated following cerulein hyperstimulation. Digestion. 1999;60:41-47.
39. Hofken T, Keller N, Fleischer F, et al. Map kinase phosphatases (MKP's) are early responsive genes during induction of cerulein hyperstimulation of pancreatitis. Biochem Biophys Res Commun. 2000;276:680-685.
40. Fleisher F, Dabew R, Goke B, et al. Stress kinase inhibition modulates acute experimental pancreatitis. World J Gastroenterol. 2001;7:259-265.
41. Mayer J, Rau B, Gansauge F, et al. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut. 2000;47:546-552.
42. Lampel M, Kern HF. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch A Pathol Anat Histol. 1977;373:97-117.
43. Kojima M, Ito T, Oono T, et al. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas. 2005;30:62-70.
44. Laemmle UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
45. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gel to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350-4354.
46. Seta T, Noguchi Y, Shimada T, et al. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:1287-1293.
47. Widmann C, Gibson S, Jarpe MB, et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79:143-180.
48. Clemons AP, Holstein DM, Galli A, et al. Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059. Pancreas. 2002;25:251-259.
49. Wagner AC, Mazzucchelli L, Miller M, et al. CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2000;278:165-172.
50. Niederau C, Ferrell LD, Grendell JH. Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin. Gastroenterology. 1985;88:1192-1204.